By year 2025 pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer related death. However, other than improved chemotherapy and a small molecule inhibitor of the epidermal growth factor receptor (EGFR), no targeted drugs are currently available. Repurposing of approved drugs might offer a rapid solution. We employed an animal PDAC model, expressing a mutant and a wild type form of p53 and KRAS, respectively. Cetuximab, a clinically approved anti-EGFR monoclonal antibody (mAb) weakly inhibited PDAC xenografts, similar to trastuzumab, a mAb against HER2, a co-receptor of EGFR. Because the combination of cetuximab and trastuzumab only moderately enhanced the anti-tumor effects, we combined each with a...
Purpose: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) wi...
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase ...
International audienceThe human EGF receptor (HER/EGFR) family of receptor tyrosine kinases serves a...
By year 2025 pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause ...
PURPOSE: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR...
International audienceUnresectable pancreatic cancer is still an extremely dismal prognosis. The con...
International audienceBACKGROUND: Pancreatic carcinoma remains a treatment-refractory cancer with a ...
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EG...
International audienceWe previously demonstrated the synergistic therapeutic effect of the cetuximab...
PURPOSE: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) wi...
Pancreatic cancer has a dismally low survival rate, due to inadequate understanding of the processes...
AbstractWe previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epiderm...
Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early locoregional spre...
Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early locoregional spre...
International audienceFive-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remain...
Purpose: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) wi...
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase ...
International audienceThe human EGF receptor (HER/EGFR) family of receptor tyrosine kinases serves a...
By year 2025 pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause ...
PURPOSE: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR...
International audienceUnresectable pancreatic cancer is still an extremely dismal prognosis. The con...
International audienceBACKGROUND: Pancreatic carcinoma remains a treatment-refractory cancer with a ...
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EG...
International audienceWe previously demonstrated the synergistic therapeutic effect of the cetuximab...
PURPOSE: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) wi...
Pancreatic cancer has a dismally low survival rate, due to inadequate understanding of the processes...
AbstractWe previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epiderm...
Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early locoregional spre...
Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early locoregional spre...
International audienceFive-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remain...
Purpose: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) wi...
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase ...
International audienceThe human EGF receptor (HER/EGFR) family of receptor tyrosine kinases serves a...